Regenxbio (NASDAQ: RGNX) reported Q4 EPS of ($1.01), $0.12 better than the analyst estimate of ($1.13). Revenue for the quarter came in at $21.21 million versus the consensus estimate of $23.47 million.

For earnings history and earnings-related data on Regenxbio (RGNX) click here.